Aim at Melanoma

What it reported doing in 2025

Websiteaim at melanoma ("aim") is the largest international organization engaged in a wide range of global patient advocacy initiatives for the purpose of raising awareness about melanoma and supporting those impacted by the disease by providing comprehensive education, advocating for patients and their families, and funding collaborative research initiatives. Among our most important contributions to the melanoma community is the ownership and maintenance of the most comprehensive u.s. Website on melanoma (www.aimatmelanoma.org). In 2025, aim continued to create website content for the purpose of meeting the needs of the melanoma community. This included, but was not limited to, making it easier for users to identify pertinent information to assist them in better understanding their melanoma diagnosis and staging, treatment options, clinical trial opportunities, recognition and management of the side effects of treatment, risk of recurrence, follow-up care, and the psychosocial aspects of the disease. The organization continued to use various methods, such as search engine optimization, social media, and brochures distributed to healthcare providers throughout the u.s, and other regions of the world and to broaden our reach and to educate patients and their families about the website's resources. The website was updated regularly for medical accuracy in order to reflect the current standard of care in melanoma and with content related to issues facing the melanoma community. As part of aim's commitment to equity in melanoma education, aim invested in global accessibility, making sure language was not a barrier to lifesaving information. Among other things, aim's website was configured for multiple languages, providing full-site translation so that the information could reach a broader audience. Aim also started the process of translating many educational materials into spanish. Aim's website alone had around 100,000 unique visitors each month. This is an increase from 2024. Approximately half of the website's traffic came from outside of the U.S.patient advocacythroughout 2025, aim continued to provide a free oncology physician assistant on call service through its ask an expert initiative. Patients with melanoma, caregivers, and families reached out to ask questions about, among other things, their/their loved one's melanoma diagnosis, treatment options, clinical trials, side effect management, and follow-up care as well as questions regarding prevention and early detection of the disease. Aim continued to coordinate numerous patient advocacy events, which included 10 patient and caregiver symposia led by nationally recognized oncologists who specialize in melanoma at major cancer centers such as sidney comprehensive cancer at johns hopkins, Michigan rogel comprehensive cancer center, carbone cancer center at uw-madison and upmc hillman cancer center. The symposia are offered as hybrid events so that individuals can attend in-person but can also watch via live stream. Aim also videotaped and edited these symposia, which were then uploaded onto youtube and aim's website so they could be viewed by individuals in the u.s. And worldwide at any time. Aim continued to provide support for patients, families, and survivors through a program called peer connect. Peer connect is a peer-to-peer support program, aim at melanoma's answer to the ongoing need for support in the melanoma community. Patients with melanoma, family members, and caregivers who join the program are matched with a peer, and from there the pair communicate in a way that is comfortable for both. Members of peer connect provide each other with knowledge, experience, emotional support, and more. In response to a first-ever fda-approved treatment option using til therapy, aim developed a peer-to-peer program specific to this patient population by matching "mentors" to those undergoing the therapy to guide others in self-advocacy, and provide meaningful emotional suppo

Financial Efficiency

• Mission deployment rate: 71.3%; rating input score 71
• Program expense ratio: 89.3%; rating input score 89
• Fundraising efficiency: $22.44 raised per $1 spent on fundraising; rating input score 62; 62nd percentile among comparable filings

Transparency & Controls

• Consistency checks: 94.1%; rating input score 94; 23rd percentile among comparable filings
• Pay-setting controls: 2 of 6 controls in place; rating input score 33
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Missing
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: 100%; rating input score 100; 75th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 80%; rating input score 80; 16th percentile among comparable filings
• Governance controls: 7 of 8 controls in place; rating input score 88
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Fail
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 23%; rating input score 76; 76th percentile among comparable filings
• Total-asset coverage ratio: 3.53; rating input score 74; 74th percentile among comparable filings
• Liabilities to assets ratio: 0; rating input score 88; 88th percentile among comparable filings
• Officer compensation ratio: 19.5%; rating input score 16; 16th percentile among comparable filings

Growth

• Program expense growth: 4.5% per year; rating input score 100; 33rd percentile among comparable filings
• Revenue growth: 7.1% per year; rating input score 100; 52nd percentile among comparable filings
• Asset growth: 14.3% per year; rating input score 100; 72nd percentile among comparable filings